ACHN – Initiating Coverage

Achillion: Initiating Coverage Background: Achillion is a small biotech focused on the development of a cure for Hepatitis C. It has several compounds in its pipeline, all unpartnered. The two.

ARQL – Initiating Coverage

ArQule Inc.(NASDAQ: ARQL) is a mid-stage small molecule drug company that specializes in the development of tyrosine kinase inhibitors(TKIs). Their in-house drug development program, ArQule Kinase Inhibitor Platform (AKIP™), produced.

GILD – Does Pharmasset Acquisition Make Gilead A Growth Company Again?

Does Acquisition Of Pharmasset Make Gilead A Growth Stock Again? Gilead stock has been stagnant for years as growth in its core HIV franchise has slowed. Acquisitions out designed to.

VRUS – Pharmasset Stock Falling- How To Play It

Pharmasset Stock Falling- How to Play It Pharmasset (VRUS) stock has fallen steadily since November 21st when the company announced it had decided to sell itself to Gilead (GILD) for.

Clinical data expected by end of 2011

This post is meant to highlight some of the key data that is expected by year’s end 2011. We have highlighted some of those catalysts which should have a significant.

INCY – Stock Running Ahead Of ASH

Incyte Corp: Stock Running Ahead Of ASH Despite today’s slight pull-back, Incyte stock is finally making a comeback. It appears the company’s discussions at the November 29th Piper Jaffray Healthcare.

Regulatory catalysts expected by end of 2011

This post is meant to highlight some of the key regulatory decisions that are expected by year’s end 2011. We have highlighted some of those catalysts which should have a.

PFE & BMY – Quick Update on Pfizer’s and Bristol’s Apixaban

  In the past week Bristol Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) have had two notably regulatory events for Apixiban, or ELIQUIS. On November 25th, the National Institute for Health.

MNTA – Quick update on Momenta

Yesterday, we saw Momenta Pharmaceuticals (NASDAQ: MNTA) gain 12% on above average volume following some subtle court news that was not picked up by any news providers. Following Momenta’s win.

ASH Stock Preview

2011 ASH Stock Preview It’s the end of the year, which can mean only one thing- the American Society of Hematology Convention is coming up! ASH is the year’s largest.

YMI – YM Biosciences- A Quick Take

YM Biosciences- A Quick Take Tuesday, November 22 saw some wild moves in this stock, which plunged close to 38% in early afternoon trading before recovering for a 9.4% loss on the day. An.

PFE & BMY – The anticoagulant market & the Apixaban Catalyst

Background: The market for anti-thrombosis agents is set for dramatic changes.  A thrombus is an aggregation of platelets which plays a key part in several life-threatening diseases, such as myocardial.

Clinical database updates

We got a chance over the past weekend to update the clinical database. After doing so, we felt the need to quickly highlight some potential catalysts. These events are likely.

GILD – Gilead To Acquire Pharmasset For $11 Billion

Gilead To Acquire Pharmasset For $11 Billion Gilead has agreed to buy HCV drug developer Pharmasset Inc. for $11 billion in cash. The deal calls for payment of $137 per.

INCY – Incyte’s Drug Receives FDA Approval- Update

Incyte Receives Approval For JAK Inhibitor In Myelofibrosis Following a trend begun earlier this year, the FDA skipped ODAC and approved another innovative cancer drug before its PDUFA date. Incyte’s.

MNTA: Initiating Coverage

Overview Momenta Pharmaceuticals(NASDAQ:MNTA) is a biotechnology company that specializes in the development of complex generic and novel drugs. Momenta specializes in the detailed structural characterization and engineering of complex sugars.

ARIA – Initiate Coverage on Ariad

ARIAD Pharmaceuticals: Initiate Coverage Overview Ariad is a clinical stage biotech company with three compounds in development, ranging from Phase I to NDA submission. The most important of these is.

SNTS – Initiating Coverage on Santarus

On November 8th, Santarus (NADSAQ:SNTS) reported third quarter earnings of $0.01 per share, which was in-line with estimates. Interesting to note, SNTS management has guided higher on Glumetza sales, and.

DEPO, XNPT, PFE – Managed-care to stunt Lyrica, Horizant and Gralise with step-edits

The Neurology and Pain sectors have been very interesting for biotech investors focused over the past year. Xenoport (NASDAQ:XNPT), Depomed (NASDAQ:DEPO), GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have all had regulatory.

EXEL – Exelixis Update November 2, 2011- FDA Denies SPA

Exelixis Update November 2, 2011- FDA Denies SPA After hours on Halloween, Exelixis announced it could not reach an agreement with the FDA for the design of its pivotal ‘306.

Browsing 20 / 468 articles